DHB Fundamental Analysis - DELIVRA HEALTH BRANDS INC

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to DHB. DHB was compared to 32 industry peers in the Pharmaceuticals industry. The financial health of DHB is average, but there are quite some concerns on its profitability. While showing a medium growth rate, DHB is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

DHB had negative earnings in the past year.

In the past year DHB has reported a negative cash flow from operations.

DHB had negative earnings in 4 of the past 5 years.

DHB had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

DHB has a Return On Assets of -8.86%. This is comparable to the rest of the industry: DHB outperforms 43.75% of its industry peers.

DHB has a Return On Equity of -18.62%. This is comparable to the rest of the industry: DHB outperforms 50.00% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8.86%
ROE	-18.62%
ROIC	N/A

ROA(3y)-1.81%

ROA(5y)-43.05%

ROE(3y)-5.55%

ROE(5y)-101.64%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 49.16%, DHB is in the better half of the industry, outperforming 71.88% of the companies in the same industry.

DHB's Gross Margin has improved in the last couple of years.

DHB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	49.16%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y6.54%

GM growth 5Y20.78%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

DHB does not have a ROIC to compare to the WACC, probably because it is not profitable.

DHB has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for DHB has been increased compared to 5 years ago.

DHB has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -19.18, we must say that DHB is in the distress zone and has some risk of bankruptcy.

DHB's Altman-Z score of -19.18 is on the low side compared to the rest of the industry. DHB is outperformed by 90.63% of its industry peers.

DHB has a Debt/Equity ratio of 0.43. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of DHB (0.43) is worse than 62.50% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.43
Debt/FCF	N/A
Altman-Z	-19.18

ROIC/WACCN/A

WACC7.19%

2.3 Liquidity

A Current Ratio of 3.14 indicates that DHB has no problem at all paying its short term obligations.

DHB has a better Current ratio (3.14) than 78.13% of its industry peers.

DHB has a Quick Ratio of 2.35. This indicates that DHB is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 2.35, DHB belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.14
Quick Ratio	2.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

DHB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -560.71%.

The Revenue has grown by 13.01% in the past year. This is quite good.

DHB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.44% yearly.

EPS 1Y (TTM)-560.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%81.76%

Revenue 1Y (TTM)13.01%

Revenue growth 3Y17.99%

Revenue growth 5Y11.44%

Sales Q2Q%1.39%

3.2 Future

DHB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.00% yearly.

Based on estimates for the next years, DHB will show a quite strong growth in Revenue. The Revenue will grow by 13.79% on average per year.

EPS Next Y80%

EPS Next 2Y49%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year13.99%

Revenue Next 2Y13.79%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DHB. In the last year negative earnings were reported.

Based on the Price/Forward Earnings ratio of 21.18, the valuation of DHB can be described as rather expensive.

71.88% of the companies in the same industry are more expensive than DHB, based on the Price/Forward Earnings ratio.

DHB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 36.10.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	21.18

4.2 Price Multiples

DHB's Enterprise Value to EBITDA ratio is in line with the industry average.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	15.21

4.3 Compensation for Growth

DHB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as DHB's earnings are expected to grow with 49.00% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y49%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

DHB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

DELIVRA HEALTH BRANDS INC

TSX-V:DHB (12/4/2025, 7:00:00 PM)

0.24

-0.01 (-4%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-10 2025-11-10

Earnings (Next)02-25 2026-02-25

Inst Owners1.86%

Inst Owner ChangeN/A

Ins Owners13.09%

Ins Owner ChangeN/A

Market Cap7.50M

Revenue(TTM)13.41M

Net Income(TTM)-806.00K

Analysts84.44

Price Target0.73 (204.17%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	21.18
P/S	0.56
P/FCF	N/A
P/OCF	N/A
P/B	1.73
P/tB	1.73
EV/EBITDA	15.21

EPS(TTM)-0.03

EYN/A

EPS(NY)0.01

Fwd EY4.72%

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)-0.02

OCFYN/A

SpS0.43

BVpS0.14

TBVpS0.14

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.86%
ROE	-18.62%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	49.16%
FCFM	N/A

ROA(3y)-1.81%

ROA(5y)-43.05%

ROE(3y)-5.55%

ROE(5y)-101.64%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y6.54%

GM growth 5Y20.78%

F-Score3

Asset Turnover1.48

Health

		Industry Rank	Sector Rank
Debt/Equity	0.43
Debt/FCF	N/A
Debt/EBITDA	4.42
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.14
Quick Ratio	2.35
Altman-Z	-19.18

F-Score3

WACC7.19%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-560.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%81.76%

EPS Next Y80%

EPS Next 2Y49%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)13.01%

Revenue growth 3Y17.99%

Revenue growth 5Y11.44%

Sales Q2Q%1.39%

Revenue Next Year13.99%

Revenue Next 2Y13.79%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y54.27%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year212.7%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y38.57%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y36.19%

OCF growth 3YN/A

OCF growth 5YN/A

DELIVRA HEALTH BRANDS INC / DHB.CA FAQ

Can you provide the ChartMill fundamental rating for DELIVRA HEALTH BRANDS INC?

ChartMill assigns a fundamental rating of 3 / 10 to DHB.CA.

What is the valuation status of DELIVRA HEALTH BRANDS INC (DHB.CA) stock?

ChartMill assigns a valuation rating of 3 / 10 to DELIVRA HEALTH BRANDS INC (DHB.CA). This can be considered as Overvalued.

What is the profitability of DHB stock?

DELIVRA HEALTH BRANDS INC (DHB.CA) has a profitability rating of 2 / 10.

Can you provide the financial health for DHB stock?

The financial health rating of DELIVRA HEALTH BRANDS INC (DHB.CA) is 4 / 10.

DELIVRA HEALTH BRANDS INC (DHB.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

DELIVRA HEALTH BRANDS INC / DHB.CA FAQ

Can you provide the ChartMill fundamental rating for DELIVRA HEALTH BRANDS INC?

What is the valuation status of DELIVRA HEALTH BRANDS INC (DHB.CA) stock?

What is the profitability of DHB stock?

Can you provide the financial health for DHB stock?